Building a Roadmap for Surveillance of Renal Masses Using a Modified Delphi Method to Help Achieve Consensus

• Published in: Urology (Ridgewood, N.J.) Vol. 180; pp. 168 - 175
• Main Authors: Patel, Amit K, Butaney, Mohit, Lane, Brian R, Wilder, Samantha, Johnson, Anna, Qi, Ji, Wang, Yuzhi, DiBianco, John, Herrel, Lindsey, Maatman, Thomas, Peabody, James, Rosenberg, Bradley, Seifman, Brian, Semerjian, Alice, Shetty, Sugandh, Schervish, Edward, Collins, Justin, Tandogdu, Zafer, Rogers, Craig G
• Format: Journal Article
• Language: English
• Published: United States 01.10.2023
• Subjects: Comorbidity; Consensus; Delphi Technique; Humans; Magnetic Resonance Imaging - methods; Neoplasms
• ISSN: 0090-4295; 1527-9995
• DOI: 10.1016/j.urology.2023.06.010

To establish a consensus for initial evaluation and follow-up of patients on active surveillance (AS) for T1 renal masses (T1RM). A modified Delphi method was used to gather information about AS of T1RM, with a focus on patient selection, timing/type of imaging modality, and triggers for intervention. A consensus panel of Michigan Urological Surgery Improvement Collaborative-affiliated urologists who routinely manage renal masses was formed. Areas of consensus (defined >80% agreement) about T1RM AS were established iteratively via 3 rounds of online questionnaires. Twenty-six Michigan Urological Surgery Improvement Collaborative urologists formed the panel. Consensus was achieved for 321/587 scenarios (54.7%) administered through 124 questions. Life expectancy, age, comorbidity, and renal function were most important for patient selection, with life expectancy ranking first. All tumors <3 cm and all patients with life expectancy <1 year were considered appropriate for AS. Appropriateness also increased with elevated perioperative risk, increasing tumor complexity, and/or declining renal function. Consensus was for multiphasic axial imaging initially (contrast CT for GFR >60 or MRI for GFR >30) with first repeat imaging at 3-6 months and subsequent imaging timing determined by tumor size. Consensus was for chest imaging for tumors >3 cm initially and >5 cm at follow up. Renal biopsy was not felt to be a requirement for entering AS, but useful in several scenarios. Consensus indicated rapid tumor growth as an appropriate trigger for intervention. Our consensus panel was able to achieve areas of consensus to help define a clinically useful and specific roadmap for AS of T1RM and areas for further discussion where consensus was not achieved.